crenolanib + fludarabine + cytarabine

This is a multi-agent combination therapy of **crenolanib**, **fludarabine**, and **cytarabine**. Crenolanib is an oral, selective, type I pan-FLT3 tyrosine kinase inhibitor with activity against FLT3-ITD and FLT3-TKD mutations, frequently found in acute myeloid leukemia (AML). It inhibits abnormal cell growth by blocking oncogenic FLT3 signaling. Fludarabine is a purine analog that interferes with DNA synthesis and repair, leading to cell death, and cytarabine is a pyrimidine nucleoside analog that also interferes with DNA synthesis. This combination is under investigation, primarily as induction or salvage therapy for both pediatric and adult patients with relapsed or refractory FLT3-mutated AML, aiming to enhance overall remission rates and survival outcomes by targeting leukemic cells through complementary and synergistic mechanisms[2][4][5].